AlloVir, Inc. Form 10-Q Summary
Filing identity: The supplied filing is for AlloVir, Inc. (Nasdaq: ALVR), not Kalaris Therapeutics, Inc. It covers the quarter and nine months ended September 30, 2021; financial statements are unaudited.
Business Context and Reporting Period
AlloVir is a late clinical-stage cell therapy company developing allogeneic, off-the-shelf virus-specific T-cell therapies. Its lead candidate is posoleucel, targeting six viruses and being evaluated primarily in transplant patients. Other programs include ALVR106 for respiratory viruses, ALVR109 for SARS-CoV-2, ALVR107 for hepatitis B, and paused preclinical work on ALVR108 for HHV-8-related diseases. The company has no approved products and has generated no product revenue.
Key Financial Metrics
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Research and development expense | $33.1 million in 2021 versus $17.2 million in 2020 | $79.1 million versus $32.9 million |
| General and administrative expense | $12.4 million versus $6.7 million | $34.9 million versus $13.0 million |
| Total operating expenses | $45.5 million versus $23.9 million | $114.0 million versus $45.9 million |
| Net loss | $45.5 million, or $0.72 per share, versus $23.6 million, or $0.58 per share | $114.0 million, or $1.82 per share, versus $44.6 million, or $2.93 per share |
| Net cash used in operating activities | Not separately reported for the quarter | $78.3 million versus $39.7 million |
| Cash, cash equivalents and short-term investments | $275.8 million at September 30, 2021 |
There was no product revenue, gross margin or operating margin because AlloVir had not commercialized a product. The company reported no debt financing or credit facility; liabilities were primarily operating lease liabilities, accrued expenses and amounts due to related parties.
At September 30, 2021, cash and cash equivalents were $243.2 million, short-term investments were $32.7 million, total assets were $316.5 million, and total liabilities were $49.2 million. Stockholders’ equity was $267.3 million, with an accumulated deficit of $239.1 million. Total cash, cash equivalents and restricted cash were $244.0 million.
Material Changes Versus the Prior Comparable Period
- Research and development expense increased 91% for the quarter and 140% for the nine-month period, primarily due to higher posoleucel manufacturing and clinical-trial costs, increased headcount, and spending on ALVR106 and ALVR109.
- General and administrative expense increased 85% for the quarter and 169% for the nine-month period, driven mainly by higher payroll, stock-based compensation, professional fees and insurance costs.
- Quarterly net loss increased by $21.9 million, while the nine-month net loss increased by $69.4 million.
- Operating cash burn increased by $38.5 million for the nine-month period, reflecting expanded development activity and public-company costs.
- Cash increased from $122.7 million at December 31, 2020 to $243.2 million at September 30, 2021, while short-term investments declined from $233.7 million to $32.7 million, principally because investments matured and were converted to cash.
- Stock-based compensation increased to $28.1 million for the first nine months of 2021 from $5.0 million in the prior-year period.
- The company entered into new Waltham, Massachusetts lease arrangements in September 2021, recording additional right-of-use assets and lease liabilities. Total operating lease liabilities were $31.4 million at quarter-end.
Guidance, Outlook, Commentary and Risks
- Management expected existing cash, cash equivalents and short-term investments to fund operating expenses and capital expenditures into 2023, although this estimate depends on assumptions that may prove incorrect.
- The company expected to continue incurring significant operating losses and increasing research and development expenses for the foreseeable future and stated that additional funding will be required.
- AlloVir planned to initiate a Phase 3 posoleucel study in adenovirus in adult and pediatric allogeneic HSCT recipients by the end of 2021 and a Phase 1/2 ALVR106 study in the fourth quarter of 2021.
- The planned Phase 3 CMV treatment study in allogeneic HSCT patients and the posoleucel CMV proof-of-concept study in solid-organ-transplant patients were delayed pending additional data from the multi-virus prevention program.
- Early ALVR109 clinical data were reported in September 2021. Management did not see a broad-market role for the COVID-19 program given available vaccines and therapies, but continued to evaluate potential use in inadequately served immunocompromised patients.
- ALVR108 preclinical work was paused because of declining incidence of HHV-8-associated diseases. ALVR107 IND-enabling studies were expected to be completed in the fourth quarter of 2021.
- COVID-19 remained a risk to clinical-trial enrollment, manufacturing, research-site operations, suppliers and contract manufacturers. Other principal risks include clinical and regulatory failure, manufacturing scale-up and supply constraints, dependence on third parties and BCM licenses, intellectual-property challenges, competition, key-personnel retention, stock-price volatility and the need for additional capital.
- The company had an effective $100 million at-the-market equity program as of September 30, 2021, but had made no sales under the program.
- Management reported that disclosure controls and procedures were effective at the reasonable-assurance level, with no material changes in internal control over financial reporting. No material legal proceedings were reported.
Most Important Facts for Investors to Verify
- Confirm the issuer identity: the source filing is AlloVir, Inc., despite the request identifying Kalaris Therapeutics, Inc.
- Verify the timing and results of the planned posoleucel adenovirus Phase 3 study and the ALVR106 Phase 1/2 study.
- Track additional data from posoleucel prevention studies and whether delayed CMV programs are resumed.
- Assess clinical efficacy, safety, regulatory status and manufacturing readiness for posoleucel, ALVR106 and ALVR109.
- Reconcile operating cash burn with the stated funding runway into 2023 and evaluate the timing and dilution risk of future financing.
- Review manufacturing dependencies, including ElevateBio/BaseCamp, external CMOs, single-source materials and process qualification milestones.
- Monitor stock-based compensation, lease commitments, related-party transactions with ElevateBio and potential dilution from equity awards and the ATM program.